Inactive Instrument

Horizon Therapeutics Public Limited Company

Equities

HZNP

IE00BQPVQZ61

Pharmaceuticals

This article is reserved for members

Already a member?

Log In

Not a member ?

Free registration
Health Canada Approves Horizon Therapeutics plc 's UPLIZNA® (inebilizumab for injection) for the Treatment of Neuromyelitis Optica Spectrum Disorders CI
Global markets live: Boeing, Amgen, Microsoft, Volkswagen, Tesla... Our Logo
Horizon Therapeutics Public Limited Company Announces the Cessation of Member of the Board of Directors CI
Amgen completes $27.8 bln Horizon deal RE
Amgen Completes Acquisition of Horizon Therapeutics MT
Amgen completes acquisition of Horizon Therapeutics RE
Horizon Therapeutics Public Limited Company(NasdaqGS:HZNP) dropped from NASDAQ Composite Index CI
Horizon Therapeutics Public Limited Company(NasdaqGS:HZNP) dropped from FTSE All-World Index CI
Horizon Therapeutics Public Limited Company(NasdaqGS:HZNP) dropped from S&P Global BMI Index CI
Horizon Therapeutics Public Limited Company(NasdaqGS:HZNP) dropped from S&P TMI Index CI
Horizon Therapeutics Public Limited Company(NasdaqGS:HZNP) dropped from S&P Biotechnology Select Industry Index CI
Horizon Therapeutics Public Limited Company's Equity Buyback announced on September 9, 2022, has expired. CI
Amgen Inc. completed the acquisition of Horizon Therapeutics Public Limited Company. CI
Amgen Wins Irish Court Approval to Acquire Horizon Therapeutics MT
Horizon Therapeutics Public Limited Company(NasdaqGS:HZNP) dropped from NASDAQ Biotechnology Index CI
Horizon Therapeutics Public Limited Company Announces New Analysis of Adhering to Uninterrupted Full Course of Treatment with Tepezza to Support Thyroid Eye Disease Patient Outcomes CI
EMEA Morning Briefing : Shares Seen Lower at Start of the Week DJ
Nvidia, Amgen back AI-driven drug firm Generate:Biomedicines' $273 mln fundraise RE
Horizon Therapeutics, Q32 Bio Say First Patient Dosed in Phase 2 Trial of Bempikibart in Severe Alopecia Areata MT
Q32 Bio and Horizon Therapeutics plc Announce Dosing of First Patient in Phase 2 Trial of Bempikibart for Severe Alopecia Areata CI
FTC settlement could shelter Amgen from US price cuts, taxes RE
Global markets live: Arm, Amgen, Lloyds, Novo Nordisk, Nestlé... Our Logo
News Highlights : Top Company News of the Day DJ
Health Care Up as Traders Hedge on Growth Views -- Health Care Roundup DJ
Sector Update: Health Care Stocks Rising in Late Afternoon Trading MT
Chart Horizon Therapeutics Public Limited Company
More charts
Horizon Therapeutics plc is an Ireland-based global biotechnology company. The Company is focused on the discovery, development and commercialization of medicines that address the critical needs of people impacted by rare, autoimmune and severe inflammatory diseases. The Company’s portfolio of medicines include ACTIMMUNE, BUPHENYL (sodium phenylbutyrate), PROCYSBI (cysteamine bitartrate), Prescription RAVICTI (glycerol phenylbutyrate), and other. ACTIMMUNE is part of a drug regimen used to treat Chronic Granulomatous Disease (CGD). BUPHENYL (sodium phenylbutyrate) is a tablet for oral administration and BUPHENYL (sodium phenylbutyrate) Powder for oral, nasogastric, or gastrostomy tube administration contains sodium phenylbutyrate. PROCYSBI (cysteamine bitartrate) delayed-release capsules and delayed-release oral granules is a prescription medicine used to treat nephropathic cystinosis in adults and children 1 year of age and older.
More about the company